Advertisement

Krebsprävention durch Vakzination

  • Lutz Gissmann
Chapter
Part of the Handbuch der Molekularen Medizin book series (HDBMOLEK, volume 2)

Zusammenfassung

Infektionskrankheiten sind bis heute die Ursache für eine hohe Mortalität in Ländern der 3. Welt, in erster Linie bei Neugeborenen und Kindern. Nach Schätzungen der WHO waren 1990 in diesen Ländern 44% aller Todesfälle auf Infektionen mit Parasiten, Viren oder Bakterien (z. B. Malaria, HIV oder Tuberkulose) zurückzuführen [Mackett u. Williamson 1995], in westlichen Ländern waren es 4, 4%. Empirische Maßnahmen zur Verhütung von Infektionskrankheiten werden seit langem praktiziert. So führten die Isolierung der Erkrankten, die Beseitigung von vermeintlichen Infektionsquellen — z. B. die Schließung einer öffentlichen Wasserpumpe während der Choleraepidemie 1854 in London — bis hin zur allgemeinen Verbesserung der sanitären Verhältnisse häufig zur Eindämmung der Erkrankung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altmann A, Gissmann L, Jochmus I (1994) Towards HPV vaccination. In: Minson A, Neil J, Mrae M (eds) Viruses and cancer. Cambridge University Press, Cambridge, pp 71–80Google Scholar
  2. Arbeit JM, Münger K, Howley PM, Hanahan D (1994) Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68: 4358–4364PubMedGoogle Scholar
  3. Auewarakul P, Gissmann L, Cid A (1994) Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Biol 14: 8250–8258PubMedGoogle Scholar
  4. Beasley RP, Lin CC, Hwang LT, Chein CS (1981) Hepatocellular carcinoma and hepatitis B virus. Lancet II: 1129–1133Google Scholar
  5. Bontkes HJ, Veenendal RA, Pea AS, Goedhard JG, Duijn W van, Kuiper I, Meijer JL, Lamers CBHW (1992) I subclass response to helicobacter pylori in patients with chronic active gastritis and duodenal ulcer. Scand J Gastroenterol 27: 129–133PubMedGoogle Scholar
  6. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 87: 796–802PubMedGoogle Scholar
  7. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trindinhdesquarmet C, Orth G, Schiller JT, Lowy DR (1995) Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69: 3 959–3963Google Scholar
  8. Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen FM, Hino O, Smith M, Mahon BJ, Lanier AP, London WT (1992) Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA 89: 9622–9626PubMedGoogle Scholar
  9. Bukh J, Purcell RH, Miller RH (1993) At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc Natl Acad Sci USA 90: 8234–8238PubMedGoogle Scholar
  10. Campo MS (1994) Vaccination against papillomavirus in cattle. Current Top Microbiol Immunol 186: 255–266Google Scholar
  11. Cann AJ, Chen ISY (1996) Human T-cell leukemia virus types I and II. In: Fields B, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds) Virology, 3rd edn. Raven Press, New York, pp 1849–1880Google Scholar
  12. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DA, Moore PS (1994) Identification of herpes virus-like DNA sequences in aids-associated Kaposis’ sarcoma. Science 266: 1865–1869PubMedGoogle Scholar
  13. Chen DS (1993) From hepatitis to hepatoma: lessons from type B hepatitis. Science 262: 369–370 Chen M, Lee A, Hazell S, Hu P, Li Y (1993) Immunization against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer? Zentralbl Hyg Umweltmed 280: 155–165Google Scholar
  14. Chien DY, Choo QL, Ralston R, Spaete R, Tong M, aHoughton M, Ku (1993) Persistence of HVC despite antibodies to both putative envelope glycoproteins. Lancet 342: 933PubMedGoogle Scholar
  15. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a NA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–362PubMedGoogle Scholar
  16. Choo QL, Kuo G, Ralston B (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 91: 1294–1298PubMedGoogle Scholar
  17. Chou WH, Yoneyama T, Takeuchi K, Harada H, Saito I, Miyamura T (1991) Discrimination of hepatitis C virus in liver tissue from patients with hepatocellular carcinoma by direct nucleotide sequence of amplified NA of the viral genome. J Clin Microbiol 29: 2860–2864PubMedGoogle Scholar
  18. Ciuffo G (1907) Investo positi con filtrato di verucce volgare. Giornale Italiano Delle Malattie. Veneree 48: 12–17Google Scholar
  19. Cleary ML, Epstein MA, Finerty S, Dorfman RF, Bornkamm GW, Kirkwood JK, Morgan AJ, Sklar J (1985) Individual tumors of multifocal Epstein Barr virus induced malignant lymphomas in tamarins arise from different B cell clones. Science 228: 772–774Google Scholar
  20. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA (1992) The retinoblastoma protein and the regulation of cell cycling. TIBS 17: 312–315PubMedGoogle Scholar
  21. Coursaget P, Yvonnet B, Chotard J, Sarr M, Vincelot P, N’Doye R, Diop-Mar I, Chiron JP (1986) Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senagal). Lancet II: 1143–1145Google Scholar
  22. Cross SL, Feinberg MB, Wolf JB, Holbrook NJ, Wong-Staal F, Leonhard WJ (1987) Regulation of the human interleu-kin-2 receptor alpha promoter; activation of a non-functional promoter by the transactivator gene of HTLV-I. Cell 49: 47–56PubMedGoogle Scholar
  23. De Villiers EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63: 4898–4903PubMedGoogle Scholar
  24. Delius H, Hofmann B (1994) Primer-directed sequencing of human papillomavirus types. In: Zur Hausen H (ed) Human pathogenic papillomaviruses. Springer, Berlin Heidelberg New York, pp 13–31Google Scholar
  25. Dyson N, Howley PM, Münger K, Harlow E (1989) The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934–937PubMedGoogle Scholar
  26. Eilermann V, Bang O (1908) Experimentelle Leukämie bei Hühnern. Zentralbl Bakteriol Mikrobiol Hyg 46: 595–599Google Scholar
  27. Ellis RW (1994) New technologies for making vaccines In: Plotkin SA, Mortimer EA (eds) Vaccines. Saunders, Philadelphia, pp 867–887Google Scholar
  28. Epstein MA, Morgan AJ (1986) Progress with subunit vaccines against the virus. In: Epstein MA, Achong BG (eds) The Epstein-Barr-virus. Recent advances. Heinemann, New York, pp 272–289Google Scholar
  29. Farci P, Purcell RH (1993) Natural history and experimental models. In: Zuckerman AJ, Thomas HC (eds) Viral hepatitis. Scientific basis and clinical management. Churchill Livingstone, Edinburgh London New York, pp 241–268Google Scholar
  30. Farci P, Alter HJ, Won DC (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 91: 7792–7796PubMedGoogle Scholar
  31. Feitelson MA, Zhu M, Duan LX, London WT (1993) Hepatitis B virus x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8: 1109–1117PubMedGoogle Scholar
  32. Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ (1992) Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J Gen Virol 73: 449–453PubMedGoogle Scholar
  33. Forsyth DM (1969) A longitudinal study of endemic urinary schistosomiasis in a small East African community. Bull World Health Organ 40: 771–783PubMedGoogle Scholar
  34. Geser AD, Thé G de, Lenoir G, Day NE, Williams EH (1982) Final case reporting from the Uganda prospective study of the relationship between EBV and Burkitt’s lymphoma. Int J Cancer 29: 397–400PubMedGoogle Scholar
  35. Gu SY, Huang TM, Ruan L, Miao YH, Lu H, Chu CM, Motz M, Wolf H (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane protein. Dev Biol Stand 84: 171–177PubMedGoogle Scholar
  36. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T (1990) Epstein-Barr virus in patients with lethal midline granuloma. Lancet 335: 128–130PubMedGoogle Scholar
  37. Harris C (1990) Hepatocellular carcinogenesis: recent advances and speculations. Cancer Cells 2: 146–148PubMedGoogle Scholar
  38. Herbst H, Steinbrecher E, Niedobiteck G, Young LS, Brooks L, Müller-Lantzsch N, Stein H (1992) Distribution and phenotype of Epstein Barr virus harbouring cells in Hodgkin’s disease. Blood 80: 484–491PubMedGoogle Scholar
  39. Hill MJ (1986) Microbes and human carcinogenesis. Arnold, London, pp 36–55Google Scholar
  40. Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland UA, Lampson GP (1975) Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 270: 401–404PubMedGoogle Scholar
  41. Hinrichs SH, Nerenberg M, Reynolds K, Khoury G, Jay G (1987) A transgenic mouse model for human neurofibromatosis. Science 237: 1340–1343PubMedGoogle Scholar
  42. Ho JHC (1972) Current knowledge of the epidemiology of nasopharyngeal carcinoma. In: Biggs P, Thé G de, Payne L (eds) Oncogenesis and herpes viruses. IARC, Lyon, pp 357–366Google Scholar
  43. Höhne M, Schaefer S, Seifer M, Feitelsen MA, Paul D, Gerrlich WH (1990) Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatits B virus. EMBO J 9: 1137–1145PubMedGoogle Scholar
  44. Hollsberg P, Haller DA (1993) Pathogenesis of diseases induced by human lymphotropic virus type 1 infection. N Engl J Med 328: 1173–1182PubMedGoogle Scholar
  45. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) mutations in human cancers. Science 253: 49–53PubMedGoogle Scholar
  46. Houghton M (1996) Hepatitis C virus. In: Fields B, Knipe DM, Howley PM, Chanock RM, Hirsch MS, Melnick JL, Monath TP, Roizman B (eds) Virology, 3rd edn. Raven Press, New York, pp 1035–1058Google Scholar
  47. Howley PH (1996) Papillomavirinae: the viruses and their replication. In: Fields B, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds) Virology, 3rd edn. Raven Press, New York, pp 2045–2076Google Scholar
  48. IARC monographs on the evaluation of carcinogenic risks to humans (1994a) Hepatitis viruses, vol 59. IARC, LyonGoogle Scholar
  49. IARC monographs on the evaluation of carcinogenic risks to humans (1994b) Schistosomes, liver flukes and helicobacter pylori, vol 61. IARC, LyonGoogle Scholar
  50. Iizuka N, Kohara M, Hagino-Yamagishi K, Abe S, Komatsu T, Tago K, Arita M, Nomoto A (1989) Construction of less neurovirolent polioviruses by introducing deletions into the 5’noncoding sequence of the genome. J Virol 63: 5354–5356PubMedGoogle Scholar
  51. Ikenberg H (1991) Human papillomavirus DNA in invasive genital carcinomas. In: Gross G, Jablonska S, Pfister H, Stegner HE (eds) Genital papillomavirus infections. Springer, Berlin Heidelberg New York, pp 87–112Google Scholar
  52. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC (1982) A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 218: 571–573PubMedGoogle Scholar
  53. Kastan MB, Zhan Q, Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD 45 is defective in ataxia teleangiectasia. Cell 71: 587–597PubMedGoogle Scholar
  54. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R (1990) The pr2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 343: 457–461PubMedGoogle Scholar
  55. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider HP (1993) Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 361: 742–745PubMedGoogle Scholar
  56. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K, Purcell RH, Alter HJ (1991) Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 115: 367–369PubMedGoogle Scholar
  57. Klingelhutz AJ, Foster SA, McDougall JK (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380: 79–82PubMedGoogle Scholar
  58. Krugman S, Giles JP, Hammond J (1970) Hepatits C virus: effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strain. J Infect Dis 122: 432–436PubMedGoogle Scholar
  59. Linke HK, Miller FH, Peterson D (1987) Documentation of non-A, non-B hepatitis in a chimpanzee with hepatocellular carcinoma. In: Robinson W, Koike K, Will H (eds) Hepadna viruses. Liss, New York, pp 357–370Google Scholar
  60. Mackett M, Williamson JD (1995) Human vaccines and vaccination. Bios Scientific Publishers, OxfordGoogle Scholar
  61. Marshall BJ (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet I: 1273–1275Google Scholar
  62. Maruyama I, Shibuya H, Harada H, Hatakeyama M, Seiki M, Fujita T, Inoue J, Yoshida M, Taniguchi T (1987) Evidence for aberrant activation of the interleukin-2 auto-krine loop by HTLV-I encoded p40xl and T3/Ti complex triggering. Cell 48: 343–350PubMedGoogle Scholar
  63. Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, Denis F, Diop-Mar I (1981) Efficacy of hepatitis B vaccine in prevention of early HBg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet I: 289–292Google Scholar
  64. McFaydan J, Hobday F (1898) Notes on the experimental transmission of warts in the dog. J Comp Pathol Ther 11: 342–346Google Scholar
  65. McMahon BJ, Rhoades ER, Heyward WL, Tower E, Ritter D, Lanier AP, Wainwright RB, Helminiak C (1987) A comprehensive program to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet II: 1134–1136Google Scholar
  66. Miller RH, Purcell RH (1990) Hepatits C virus shares aminoacid sequence similarity with pestiviruses and flavi-viruses as well as members of two plant virus subgroups. Proc Natl Acad Sci USA 87: 2057–2061PubMedGoogle Scholar
  67. Mondelli MU, Colombo M (1991) The emerging picture of hepatitis C. Dig Dis 9: 245–252PubMedGoogle Scholar
  68. Morgan AJ (1992) Epstein-Barr virus vaccines. Vaccine 10: 563–571PubMedGoogle Scholar
  69. Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, Epstein MA (1988) Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cotton top tamarins against EB virus-induced malignant lymphomas. J Med Virol 25: 189–195PubMedGoogle Scholar
  70. Murphy FA (1996) Virus taxonomy. In: Fields B, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds) Virology, 3rd edn. Raven Press, New York, pp 15–57Google Scholar
  71. Nagaya T, Nakamura T, Tokino T, Tsurimoto T, Imai M, Mayumi T, Kamino K, Yamamura K, Matsubura K (1987) The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1: 773–782PubMedGoogle Scholar
  72. Nakamura H, Hayami M, Ohta Y, Ishikawa K, Tsujimoto H, Kiyokawa T, Yoshida M, Sasagawa A, Honjo S (1987) Pretection of cynomolgus monkeys against infection by human T cell leukemia virus type-I by immunization with viral env gene products produced in E. coli. Int J Cancer 40: 403–407Google Scholar
  73. Noach LA, Bosma NB, Jansen J, Haeck FJ, Deventer SJH van, Tytgat GNJ (1994) Mucosal tumor necrosis factor-a, in-terleukin-lß and interleukin-8 production in patients with helicobacter pylori infection. Scand J Gastroenterol 29: 425–429PubMedGoogle Scholar
  74. Parkin DM, Laara E, Muir CS (1988) Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41: 184–197PubMedGoogle Scholar
  75. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J (eds) (1992) Cancer incidence in five continents, vol VI. IARC scientific publications No. 120. IARC, Lyon, pp 182–193Google Scholar
  76. Payne LN (1994) Marek’s disease virus. In: Webster RG, Granoff A (eds) Encyclopedia of virology. Academic Press, New York London, pp 832–837Google Scholar
  77. Pel PK (1899) Ziekten van de Maag. De Erven F Bohn, AmsterdamGoogle Scholar
  78. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77: 7415–7419PubMedGoogle Scholar
  79. Popper H, Roth L, Purcell RH, Tennant BC, Gerin JL (1987) Hepatocarcinogenesis of the woodchuck hepatitis virus. Proc Natl Acad Sci USA 84: 866–870PubMedGoogle Scholar
  80. Rickinson AB, Kieff E (1996) Epstein Barr virus. In: Fields B, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds) Virology, 3rd edn. Raven Press, New York, pp 2397–2446Google Scholar
  81. Rigoni-Stern D (1842) Fatti statistici relativi alle malatie cancerose. G Serv Prog Pathol Ther 2: 507–519Google Scholar
  82. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT (1996) Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70: 3298–3301PubMedGoogle Scholar
  83. Rous P (1911) A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 13: 397–399PubMedGoogle Scholar
  84. Rous P, Beard JW (1934) The progression to carcinoma of virus-induced rabbit papilloma (shope). J Exp Med 62: 523–528Google Scholar
  85. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136PubMedGoogle Scholar
  86. Schiffman MH (1994) Epidemiology of cervical human papillomavirus infections. In: Zur Hausen H (ed) Human pathogenic papillomaviruses. Springer, Berlin Heidelberg New York, pp 55–81Google Scholar
  87. Schiller JT, Roden RBS (1995) Papillomavirus-like particles. Papillomavirus Rep 6: 121–128Google Scholar
  88. Schmuckler EA, Ferrell L, Clawson GA (1984) Proliferative hepatocellular lesions, benign and malignant. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune & Stratton, New York, pp 201–207Google Scholar
  89. Seto A, Kawanishi M, Matsuda S, Ogawa K, Miyoshi I (1988) Adult T-cell leukemia-like disease experimentally induced in rabbits. Jpn J Cancer Res 79: 335–341PubMedGoogle Scholar
  90. Shah KV, Howley PM (1996) Papillomaviruses. In: Fields B, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds) Virology, 3rd edn. Raven Press, New York, pp 2077–2110Google Scholar
  91. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, Zur Hausen H, Villiers EM de (1994) Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 54: 4610–4613PubMedGoogle Scholar
  92. Shida H, Tochikura T, Sato T, Konno T, Hirayoshi K, Seki M, Ito Y, Hatanaka M, Hinuma Y, Sugimoto M (1987) Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I expression. EMBO J 6: 3379–3384PubMedGoogle Scholar
  93. Sidebotham RL, Batten JJ, Karim QN, Spencer J, Baron JH (1991) Breakdown of gastric mucus in presence of helicobacter pylori. J Clin Pathol 44: 52–57PubMedGoogle Scholar
  94. Simmonds P, Holmes EC, Cha TA, Chan SW, Mmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74: 2391–2399PubMedGoogle Scholar
  95. Snijders PJF, Brule AJC van den, Meijer CJLM, Walboomers JMM (1994) Papillomaviruses and cancer of the upper digestive and respiratory tracts. In: Zur Hausen H (ed) Human pathogenic papillomaviruses. Springer, Berlin Heidelberg New York, pp 177–198Google Scholar
  96. Sonnex C (1995) The clinical features of genital and perigenital human papillomavirus infection. In: Mindel A (ed) Genital warts: human papillomavirus infection. Arnold, London, pp 82–104Google Scholar
  97. The Gambia hepatitis study group (1987) The Gambia hepatitis intervention study. Cancer Res 47: 5782–5787Google Scholar
  98. Thé G de (1982) Epidemiology of Epstein Barr virus and associated diseases. In: Roizman B (ed) The herpesviruses, vol 1. Plenum Press, New York, pp 25–87Google Scholar
  99. Thé G de, Bomford R, Kazanji M, Ibrahim F (1994) Human T cell lymphotropic virus: necessity for and feasibility of a vaccine. Ciba Found Symp 187: 47–55PubMedGoogle Scholar
  100. Thorey-Lawson DA, Geilinger K (1980) Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein Barr virus neutralize infectivity. Proc Natl Acad Sci USA 77: 3507–3511Google Scholar
  101. Tiollais P, Pourcel C, Dejean A (1985) The Hepatitis B virus. Nature 317: 489–495PubMedGoogle Scholar
  102. Tur-kasta R, Burk RD, Shaul Y, Shafritz DA (1986) Hepatitis B virus DNA contains a glucocorticoid responsive element. Proc Natl Acad Sci USA 83: 1627–1631Google Scholar
  103. Ulmer JB, Donnelly J, Parker SE, Rhodes DH, Feigner PL, Dwarki VL, Grombowski SH, Deck R, Devitt CM, Friedman A, Hawe LA, Leander KR, Marinez D, Perry H, Shiver JW, Montgomery D, Liu MA (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745–1749PubMedGoogle Scholar
  104. Vousden KH, Farrell PJ (1994) Viruses and human cancer. Br Med Bull 50: 560–581PubMedGoogle Scholar
  105. Warren JR (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet I: 1273Google Scholar
  106. Whittle HC, Lamb WH, Ryder RW (1987) Trials of intradermal hepatitis B vaccines in Gambian children. Ann Trop Paediatr 7: 6–9PubMedGoogle Scholar
  107. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S (1991) Vaccination against hepatitis B and protection against chronic viral carriage in the Gambia. Lancet 337: 747–750PubMedGoogle Scholar
  108. WHO (1993) The control of schistosomiasis. Second report of the WHO expert committee. WHO Tech Rep Ser 830Google Scholar
  109. Wolf H, Zur Hausen H, Becker Y (1973) EBV viral genomes in epithelial nasopharyngeal carcinoma cells. Nat Biol 244: 245–257Google Scholar
  110. Zerfaß K, Schulze A, Spitkovsky D, Friedman V, Henglein B, Jansen-Dürr P (1995) Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus 16 E7 through sequences necessary for transformation. J Virol 69: 6389–6399PubMedGoogle Scholar
  111. Zur Hausen (1976) Condylomata acuminata and human genital cancer. Cancer Res 36: 794PubMedGoogle Scholar
  112. Zur Hausen (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184: 9–13PubMedGoogle Scholar
  113. Zur Hausen H, Schulte-Holthausen H, Klein G (1970) EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature 228: 1956–1958Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Lutz Gissmann

There are no affiliations available

Personalised recommendations